Achmea Investment Management B.V. Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Achmea Investment Management B.V. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 93.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,914 shares of the medical research company’s stock after selling 29,356 shares during the quarter. Achmea Investment Management B.V.’s holdings in IQVIA were worth $376,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of IQV. Raymond James Financial Inc. acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $236,120,000. FMR LLC grew its stake in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $147,683,000. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Up 2.2 %

Shares of NYSE:IQV opened at $185.40 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $32.69 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The firm’s 50-day moving average is $196.63 and its two-hundred day moving average is $210.69. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $256.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.